LEHI, Utah / Feb 26, 2025 / Business Wire / Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, announced today that it will participate in TD Cowen's 45th Annual Health Care Conference on March 5, 2025 at the Boston Marriott Copley Place. Kurt Workman, Owlet’s Chief Executive Officer and Co-Founder, Jonathan Harris, President and Chief Revenue Officer, and Amanda Twede-Crawford, Chief Financial Officer, are scheduled to engage in a fireside chat on Wednesday, March 5, 2025, at 9:50 a.m. ET.
A link to the live webcast of the fireside chat will be available on the Owlet Investor Relations website, investors.owletcare.com. A replay of the webcast will also be available on Owlet’s Investor Relations website.
About Owlet, Inc.
Owlet’s digital health infant monitoring platform is transforming the journey of parenting. The Company (NYSE: OWLT), a small-cap healthcare growth equity, offers FDA-authorized medical and consumer pediatric wearables and an integrated HD visual and audio camera that provide real-time data and insights to parents who safeguard health, optimize wellness, and ensure peaceful sleep for their children.
Since 2012, over two million parents worldwide have used Owlet’s platform contributing to one of the largest collections of consumer infant health and sleep data. The Company continues to develop software and digital data solutions to bridge the current healthcare gap between hospital and home and bring new insights to parents and caregivers globally. Owlet believes that every child deserves to live a long, happy, and healthy life.
To learn more, visit www.owletcare.com.
Last Trade: | US$4.03 |
Daily Change: | 0.15 3.87 |
Daily Volume: | 11,269 |
Market Cap: | US$64.640M |
March 04, 2025 January 28, 2025 September 13, 2024 September 11, 2024 September 03, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load